BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1172 related articles for article (PubMed ID: 26723869)

  • 21. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
    J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson's disease.
    Kim JI; Yang EJ; Lee MS; Kim YS; Huh Y; Cho IH; Kang S; Koh HK
    Int J Neurosci; 2011 Apr; 121(4):209-17. PubMed ID: 21265705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective effects of Astilbin on MPTP-induced Parkinson's disease mice: Glial reaction, α-synuclein expression and oxidative stress.
    Zhu YL; Sun MF; Jia XB; Cheng K; Xu YD; Zhou ZL; Zhang PH; Qiao CM; Cui C; Chen X; Yang XS; Shen YQ
    Int Immunopharmacol; 2019 Jan; 66():19-27. PubMed ID: 30419450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Papaverine inhibits α-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinson's disease.
    Leem YH; Park JS; Park JE; Kim DY; Kang JL; Kim HS
    Biomed Pharmacother; 2020 Oct; 130():110576. PubMed ID: 32768884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson's disease.
    Selvakumar GP; Janakiraman U; Essa MM; Justin Thenmozhi A; Manivasagam T
    Brain Res; 2014 Oct; 1585():23-36. PubMed ID: 24657313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress.
    Chen XC; Zhou YC; Chen Y; Zhu YG; Fang F; Chen LM
    Acta Pharmacol Sin; 2005 Jan; 26(1):56-62. PubMed ID: 15659115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways.
    Park JS; Choe K; Lee HJ; Park TJ; Kim MO
    J Biomed Sci; 2023 Aug; 30(1):66. PubMed ID: 37568205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
    Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
    Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
    Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
    FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
    J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acupuncture Inhibits the Increase in Alpha-Synuclein in Substantia Nigra in an MPTP- Induced Parkinsonism Mouse Model.
    Yeo S; Song J; Lim S
    Adv Exp Med Biol; 2020; 1232():401-408. PubMed ID: 31893437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
    Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
    J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation.
    Li Y; Liu W; Li L; Hölscher C
    Eur J Pharmacol; 2017 Feb; 797():162-172. PubMed ID: 27913104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson's Disease Model in Mice.
    Mani S; Sekar S; Barathidasan R; Manivasagam T; Thenmozhi AJ; Sevanan M; Chidambaram SB; Essa MM; Guillemin GJ; Sakharkar MK
    Neurotox Res; 2018 Apr; 33(3):656-670. PubMed ID: 29427283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
    Finkelstein DI; Billings JL; Adlard PA; Ayton S; Sedjahtera A; Masters CL; Wilkins S; Shackleford DM; Charman SA; Bal W; Zawisza IA; Kurowska E; Gundlach AL; Ma S; Bush AI; Hare DJ; Doble PA; Crawford S; Gautier EC; Parsons J; Huggins P; Barnham KJ; Cherny RA
    Acta Neuropathol Commun; 2017 Jun; 5(1):53. PubMed ID: 28659169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3.
    Li D; Yang H; Ma J; Luo S; Chen S; Gu Q
    Hum Cell; 2018 Apr; 31(2):106-115. PubMed ID: 29274035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects.
    Burks S; Raymick J; Robinson B; Hanig J; Sarkar S
    Neurosci Lett; 2019 Jun; 703():86-95. PubMed ID: 30890473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.